Evidence map›Paper›PMID 42178880›Full record

ArticlePhysiological reports2026

COX2

Momo Goto, Tamaki Kurosawa, Hiroyuki Koike, Noriyuki Kaji, Ichiro Manabe, Taiki Mihara, Takashi Chaen, Yumiko Oishi, Masatoshi Hori

Abstract read
In one paragraph

Article in Physiological reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Momo GotoLaboratory of Veterinary Pharmacology, Department of Veterinary Medical Sciences, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Tamaki KurosawaLaboratory of Veterinary Pharmacology, Department of Veterinary Medical Sciences, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.ORCID 0000-0002-8453-1567
Hiroyuki KoikeDepartment of Medical Biochemistry, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
Noriyuki KajiLaboratory of Veterinary Pharmacology, School of Veterinary Medicine, Azabu University, Sagamihara, Kanagawa, Japan.
Ichiro ManabeDepartment of Systems Medicine, Graduate School of Medicine, Chiba University, Chiba, Chiba, Japan.
Taiki MiharaLaboratory of Veterinary Pharmacology, Department of Veterinary Medical Sciences, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Takashi ChaenLaboratory of Veterinary Pharmacology, Department of Veterinary Medical Sciences, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Yumiko OishiDepartment of Medical Biochemistry, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
Masatoshi HoriLaboratory of Veterinary Pharmacology, Department of Veterinary Medical Sciences, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.

Funding

MEXT | Japan Science and Technology Agency (JST) JPMJFR2351MEXT | Japan Society for the Promotion of Science (JSPS) 19H03125MEXT | Japan Society for the Promotion of Science (JSPS) 22K15008MEXT | Japan Society for the Promotion of Science (JSPS) 22KJ2353MEXT | Japan Society for the Promotion of Science (JSPS) 23H02379MEXT | Japan Society for the Promotion of Science (JSPS) 23H02912MEXT | Japan Society for the Promotion of Science (JSPS) 23KJ0510MEXT | Japan Society for the Promotion of Science (JSPS) 24K18016Takeda Science Foundation (TSF)The University of Tokyo R4 Excellent Young Reseacher
6 · The paper itself

Abstract

Liver fibrosis is a growing global health problem with no effective treatments. PDGFRα-positive fibroblasts are the main drivers of liver fibrosis, but their cellular heterogeneity is not fully understood. In this study, we performed single-cell RNA sequencing (scRNA-seq) on PDGFRα-positive fibroblasts isolated from healthy mouse livers. We also induced liver fibrosis via bile duct ligation (BDL) and examined their interactions with immune cells. scRNA-seq revealed that PDGFRα-positive fibroblasts mainly consist of hepatic stellate cells and portal fibroblasts. CellChat analysis indicated that a COX2-high (Ptgs2-high) subpopulation may preferentially interact with immune cells. This COX2-positive PDGFRα-positive fibroblast subset, also reported in other organs, localizes around bile ducts in the liver. Furthermore, when FACS-sorted PDGFRα-positive fibroblasts were treated with IL-1β in vitro, the proportion of COX2-positive cells increased. These findings demonstrate that PDGFRα-positive fibroblasts exhibit diversity in their responses to immune signals, with the COX2-positive subset potentially playing a key role in early fibrotic responses. Clarifying this heterogeneity may improve understanding of early liver fibrosis and support development of new therapeutic strategies.

Indexed as

Bile DuctsCyclooxygenase 2FibroblastsLiver CirrhosisReceptor, Platelet-Derived Growth Factor alphaAnimalsHepatic Stellate CellsLiverMaleMiceMice, Inbred C57BLCyclooxygenase 2Ptgs2 protein, mouseReceptor, Platelet-Derived Growth Factor alphaCOX2fibroblastliver fibrosisPDGFRαsingle cell RNA sequencing

Identifiers

PMID42178880
PMCPMC13240249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.